Overview of therapeutic drug research for COVID-19 in China.
Acta Pharmacol Sin
; 41(9): 1133-1140, 2020 Sep.
Article
in English
| MEDLINE | ID: covidwho-608476
ABSTRACT
Since the outbreak of novel coronavirus pneumonia (COVID-19) in December 2019, more than 2,500,000 people worldwide have been diagnosed with SARS-CoV-2 as of April 22. In response to this epidemic, China has issued seven trial versions of diagnosis and treatment protocol for COVID-19. According to the information that we have collected so far, this article provides an overview of potential therapeutic drugs and compounds with much attention, including favipiravir and hydroxychloroquine, as well as traditional Chinese medicine, which have been reported with good clinical treatment effects. Moreover, with further understanding of SARS-CoV-2 virus, new drugs targeting specific SARS-CoV-2 viral components arise and investigations on these novel anti-SARS-CoV-2 agents are also reviewed.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Pneumonia, Viral
/
Coronavirus Infections
/
Pandemics
/
Betacoronavirus
/
Medicine, Chinese Traditional
Type of study:
Prognostic study
/
Randomized controlled trials
Topics:
Traditional medicine
Limits:
Humans
Language:
English
Journal:
Acta Pharmacol Sin
Journal subject:
Pharmacology
Year:
2020
Document Type:
Article
Affiliation country:
S41401-020-0438-y
Similar
MEDLINE
...
LILACS
LIS